Company intelligence / Profile preview

Virttu Biologics

Glasgow, Scotland, United Kingdomcancerresearchhorizons.com ↗

Ownership: Private
Development stage: Other

Overview

Crusade Laboratories developed HSV1716, a modified herpes simplex virus type 1 that selectively invades and kills tumor cells while sparing normal tissue. The company reported promising results from Phase I clinical trials and preclinical animal studies demonstrating tumor selectivity and efficacy.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Virttu Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virttu Biologics.

Explore the full profile